Bleeding Disorders — Types, Causes, Symptoms & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Bleeding disorders are a group of conditions in which the blood's normal haemostatic mechanisms — the coordinated process by which bleeding is controlled through primary haemostasis (platelet plug formation), secondary haemostasis (coagulation cascade), and fibrinolysis — are impaired, resulting in excessive, prolonged, or spontaneous bleeding from wounds, mucous membranes, joints, or internal organs. Normal haemostasis requires the precise function of three interdependent components: vascular endothelium (provides vasoconstriction and scaffolding for platelet adhesion), platelets (primary plug — activated by collagen, vWF, and thrombin), and coagulation factors (intrinsic, extrinsic, and common pathways — producing fibrin to consolidate the clot). Deficiency or dysfunction in any component can cause a bleeding disorder. Major categories: (1) Inherited coagulation factor deficiencies — haemophilia A (factor VIII deficiency — the most common severe inherited coagulation disorder, affecting 1 in 5,000 male births globally); haemophilia B/Christmas disease (factor IX deficiency — 1 in 30,000 male births); haemophilia C (factor XI deficiency — common in Ashkenazi Jewish populations); and von Willebrand disease (vWD) — the most common inherited bleeding disorder overall, affecting approximately 1% of the world population. (2) Platelet disorders: thrombocytopenia (platelet count below 150 × 10⁹/L from immune destruction, marrow failure, or consumption); qualitative platelet disorders — Glanzmann's thrombasthenia (absent GPIIb/IIIa — defective platelet aggregation), Bernard-Soulier syndrome (absent GPIb-IX-V — defective platelet adhesion), and drug-induced platelet dysfunction (aspirin, NSAIDs, clopidogrel, prasugrel). (3) Acquired disorders: liver disease (hepatic synthesis of most coagulation factors); vitamin K deficiency (required for γ-carboxylation of factors II, VII, IX, X, protein C, and protein S); anticoagulant medications (warfarin, heparin, DOACs); DIC (disseminated intravascular coagulation — pathological activation of coagulation consuming factors and platelets); and massive blood transfusion causing dilutional coagulopathy.

Inherited bleeding disorders: haemophilia A and B are X-linked recessive conditions — the gene encoding factor VIII (F8) lies on the X chromosome; affected males (XY — one X copy) have severe disease; carrier females (XX) are usually asymptomatic but may have mild factor VIII deficiency and bleeding symptoms (10-30% of carriers); spontaneous new mutations account for approximately 30% of haemophilia cases. Von Willebrand disease (vWD): autosomal inheritance (dominant for types 1 and 2, recessive for type 3 — most severe, with near-absent vWF levels); vWD type 1 (70-80% of cases — mild quantitative reduction in structurally normal vWF), type 2 (qualitative vWF defect — multiple subtypes including 2A, 2B, 2M, 2N), and type 3 (complete vWF deficiency — severe bleeding). Acquired bleeding disorders — common clinical causes: liver disease (cirrhosis — impaired hepatic synthesis of all coagulation factors except vWF; also causes thrombocytopenia from portal hypertension and hypersplenism); vitamin K deficiency (fat-soluble vitamin K is required for hepatic gamma-carboxylation of factors II/VII/IX/X and protein C/S — causes warfarin effect, biliary obstruction, fat malabsorption including coeliac disease, prolonged broad-spectrum antibiotics, and neonatal haemorrhagic disease of the newborn); immune thrombocytopenia (ITP — autoimmune anti-platelet IgG antibodies targeting GPIIb/IIIa driving macrophage clearance in the spleen — platelet counts often below 30 × 10⁹/L with acute mucocutaneous bleeding risk); DIC — triggered by sepsis (most common — particularly Gram-negative sepsis with endotoxin), obstetric emergencies (abruptio placentae, amniotic fluid embolism, HELLP syndrome), massive trauma, malignancy (acute promyelocytic leukaemia — t(15;17) AML-M3 — classically presents with DIC), and snake envenomation; heparin-induced thrombocytopenia (HIT — paradoxical thrombotic disorder from PF4-heparin antibody-induced platelet activation — occurs in 0.5-5% of unfractionated heparin recipients); thrombotic thrombocytopenic purpura (TTP — ADAMTS13 deficiency causing vWF multimer accumulation and platelet thrombi).

The pattern of bleeding differs characteristically between coagulation factor deficiencies and platelet/vascular disorders — an important clinical distinction. Coagulation factor deficiency (haemophilia) pattern — 'deep tissue bleeding': haemarthroses (bleeding into joints — the hallmark of severe haemophilia, affecting knees 45%, ankles 30%, elbows 15% — presenting with warmth, swelling, stiffness, and severe pain; 'target joints' develop from repeated bleeds); deep muscle haematomas (especially iliopsoas — causing hip flexion and femoral nerve compression, often confused with appendicitis); intracranial haemorrhage — a life-threatening emergency, the leading cause of mortality in haemophilia (approximately 4-8% lifetime risk in severe haemophilia without adequate prophylaxis); retroperitoneal haemorrhage; prolonged bleeding from cuts, lacerations, or dental extractions; delayed bleeding after minor trauma (initial primary haemostasis from platelets works, but the clot fails to consolidate without adequate factor levels). Platelet/vascular disorder pattern — 'mucocutaneous bleeding': petechiae (pinpoint 1-3 mm red/purple spots — non-blanching on pressure — from red blood cells leaking through damaged capillaries into skin; characteristic of severe thrombocytopenia — below 10-20 × 10⁹/L); purpura (confluent petechiae — 3 mm to 1 cm); echymoses (larger bruises — easy bruising from minor trauma); epistaxis (nosebleeds — often prolonged and difficult to stop); menorrhagia (heavy menstrual periods — often the presenting complaint in women with undiagnosed vWD or ITP); gum bleeding (gingival oozing); and mucosal GI or urinary bleeding. Von Willebrand disease specifically: heavy menstrual periods (80% of symptomatic vWD women); post-partum haemorrhage (significant — especially in type 2 and 3 vWD); post-dental extraction bleeding — often the diagnostic event; epistaxis; and prolonged bleeding from skin cuts. ITP severe thrombocytopenia (below 10 × 10⁹/L): risk of spontaneous intracranial haemorrhage; wet purpura (mucosal bleeding — blood blisters inside the mouth — indicates very high risk).

Initial coagulation screen: full blood count (FBC — platelet count, red cell morphology for microangiopathic changes), prothrombin time (PT, expressed as INR — measures the extrinsic pathway — factors VII, X, V, II, fibrinogen), activated partial thromboplastin time (aPTT — measures the intrinsic pathway — factors XII, XI, IX, VIII, X, V, II, fibrinogen), thrombin time (TT — measures final fibrinogen-to-fibrin conversion step), and fibrinogen level. Coagulation screen interpretation: isolated prolonged PT (elevated INR with normal aPTT): factor VII deficiency, early vitamin K deficiency, early warfarin effect; isolated prolonged aPTT (with normal PT): haemophilia A (factor VIII deficiency), haemophilia B (factor IX deficiency), haemophilia C (factor XI deficiency), vWD (von Willebrand disease — vWF acts as a carrier for factor VIII, so reduced vWF causes secondary low factor VIII), or lupus anticoagulant (antiphospholipid syndrome — paradoxically causes thrombosis despite prolonged aPTT — mixing study does not correct); both PT and aPTT prolonged: DIC (with low fibrinogen, low platelets, elevated D-dimer), liver failure, vitamin K deficiency (severe), and factor X/II/fibrinogen/factor V deficiency. Specific tests: factor VIII and IX assays (diagnosis and severity grading of haemophilia — severe below 1%, moderate 1-5%, mild 6-40%); von Willebrand factor antigen (vWF:Ag), vWF activity (ristocetin cofactor — vWF:RCo), and factor VIII level — and in specialist laboratories, vWF multimer analysis (distinguishing vWD subtypes); vWF is an acute phase protein — rises with stress, surgery, OCP, pregnancy, hypothyroidism — so testing in calm circumstances is essential. Platelet function assessment: PFA-100 (platelet function analyser — screens for platelet dysfunction and mild vWD); light transmission aggregometry (LTA) — the gold standard for diagnosing specific platelet function disorders (Glanzmann's, BSS, drug-induced dysfunction). Mixing study: aPTT of patient plasma mixed 1:1 with normal pooled plasma — correction indicates factor deficiency; non-correction indicates inhibitor (acquired haemophilia — factor VIII inhibitor) or lupus anticoagulant. Bethesda inhibitor titre quantifies factor inhibitor strength. ADAMTS13 activity for TTP (below 10% is diagnostic). D-dimer, fibrinogen degradation products (FDPs), and serial platelet count trends for DIC.

Treatment is tailored to the specific bleeding disorder type and severity. Haemophilia A — current standard of care: recombinant factor VIII (rFVIII) concentrate infusion — dose calculated by target factor level and volume of distribution (1 IU/kg raises factor VIII by approximately 2%); prophylactic therapy (regular factor infusions 3x/week or every other day) begun in early childhood prevents haemarthroses and is the current standard in developed countries for severe haemophilia (below 1% factor VIII); on-demand therapy for mild/moderate bleeds. Extended half-life (EHL) factor VIII products (rFVIIIFc — Elocta; rFVIII-PEG — Adynovi) allow less frequent prophylaxis (twice weekly). Emicizumab (Hemlibra — anti-FIXa/FX bispecific antibody): mimics factor VIII cofactor function; given subcutaneously weekly, fortnightly, or monthly; effective in all haemophilia A patients including those with inhibitors (neutralising antibodies against factor VIII — developing in 25-30% of severe haemophilia A); has transformed treatment for inhibitor patients who previously had limited options. Haemophilia B: recombinant factor IX (rFIX) concentrate; EHL products (albutrepenonacog — rFIX-albumin, eftrenonacog — rFIX-Fc) allow weekly or fortnightly dosing. Fitusiran (Alhemo — siRNA targeting antithrombin): monthly SC injection, used for haemophilia A or B with or without inhibitors. Von Willebrand disease: Type 1 vWD — DDAVP (desmopressin) 0.3 mcg/kg IV or intranasal (Octim) — stimulates endothelial vWF release from Weibel-Palade bodies, raising factor VIII and vWF levels 3-5-fold within 30-60 minutes; effective for procedures and mucosal bleeding; avoid in cardiovascular disease; tachyphylaxis with repeated use. Types 2B and 3 — vWF/factor VIII concentrate (Haemate-P, Wilate). Tranexamic acid (1g TDS orally, or 1g IV) — antifibrinolytic (inhibits plasminogen activation) — highly effective adjunct for dental procedures, menorrhagia, epistaxis, and gastrointestinal mucosal bleeding in all bleeding disorders; oral contraceptive pill and levonorgestrel IUS for menorrhagia in vWD. ITP management: first-line — prednisolone 1 mg/kg/day; IV immunoglobulin (IVIG 1-2 g/kg) for rapid platelet rise needed for emergency procedures or haemorrhage; thrombopoietin receptor agonists (TPO-RAs — eltrombopag 25-75 mg/day orally, romiplostim 1-10 mcg/kg SC weekly) for refractory ITP; rituximab (anti-CD20) for refractory autoimmune cases; splenectomy now reserved for true drug-refractory ITP. DIC treatment: treat the underlying cause (sepsis, obstetric emergency); replace consumed factors with FFP (12-15 mL/kg); cryoprecipitate for fibrinogen below 1.5 g/L; platelet transfusion if below 50 × 10⁹/L with active bleeding. TTP: plasma exchange (PEX) is life-saving — must begin within hours of diagnosis; caplacizumab (anti-vWF nanobody) reduces TTP recurrence and severity.

Recurrent haemarthroses in untreated or undertreated severe haemophilia cause chronic haemophilic arthropathy — iron deposits from repeated intra-articular bleeding activate synovial inflammation, producing progressive cartilage destruction, joint deformity (flexion contractures, valgus deformity), severe pain, reduced range of movement, and disability — often requiring total joint arthroplasty, particularly of the knee, ankle, and elbow. Intracranial haemorrhage — spontaneous (particularly in neonates) or from head trauma — remains the leading cause of death and acquired disability in untreated haemophilia; it requires immediate factor replacement to 100% level and neurosurgical assessment. Inhibitor development (neutralising antibodies against infused factor VIII or IX) occurs in 25-30% of severe haemophilia A patients treated with standard FVIII concentrates, making treatment considerably more complex and requiring bypassing agents (aPCC, recombinant FVIIa) or emicizumab prophylaxis. Uncontrolled heavy menstrual bleeding from vWD or platelet disorders causes severe iron-deficiency anaemia, chronic fatigue, and reduced quality of life. Women with bleeding disorders are frequently misdiagnosed and underdiagnosed for years — the average diagnostic delay is over 10 years for vWD in women. Surgical procedures and dentistry without coordinated haemostatic prophylaxis (factor replacement, tranexamic acid) are potentially life-threatening in severe haemophilia. Historical non-virus-inactivated plasma concentrates caused HIV (affecting 1,200 UK haemophilia patients) and hepatitis C epidemics — the contaminated blood scandal — now prevented by modern viral inactivation techniques and recombinant factor products.

Prophylactic factor replacement 3x/week in severe haemophilia A and B prevents most haemarthroses and significantly reduces arthropathy and disability. All patients with bleeding disorders should carry a medical alert card specifying their condition, factor deficiency type, and treatment. Avoid NSAIDs (ibuprofen, aspirin) which further impair platelet function — use paracetamol instead. Inform all healthcare providers (surgeons, dentists, physiotherapists) of your bleeding disorder before any procedure. Vaccinate against hepatitis A and B. Genetic counselling and prenatal testing are available for families with inherited bleeding disorders.

Call 999 or attend A&E immediately for: uncontrolled severe bleeding; sudden severe headache with confusion or weakness (possible intracranial haemorrhage); or joint haemarthrosis causing severe pain and swelling. See a GP urgently for: heavy menstrual bleeding soaking through pads or tampons hourly; frequent or prolonged nosebleeds not stopping within 20 minutes of direct pressure; prolonged bleeding after cuts, dental procedures, or minor trauma; or unexplained bruising in children. If you have an undiagnosed bleeding tendency, request a haematology referral for coagulation screen, factor levels, and von Willebrand factor testing. Never undergo any surgical procedure or dental extraction without first informing your haematologist — perioperative haemostatic cover is essential.